The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts cortisone to the active glucocorticoid cortisol, thereby acting as a cellular switch to mediate glucocorticoid action in many tissues. Several studies have indicated that 11β-HSD1 plays a crucial role in the onset of type 2 diabetes and central obesity. As a consequence, selective inhibition of 11β-HSD1 in humans might become a new and promising approach for lowering blood glucose concentrations and for counteracting the accumulation of visceral fat and its related metabolic abnormalities in type 2 diabetes. In this study, we present the synthesis and the biological evaluation of ursan or oleanan type triterpenoids which may act as selective 11β-HSD1 inhibitors in liver as well as in peripheral tissues, like adipocytes and muscle cells. In order to rationalise the outcomes of the inhibition data, docking simulations of the ligands were performed on the experimentally determined structure of 11β-HSD1. Furthermore, we discuss the structural determinants that confer enzymatic specificity. From our investigation, valuable information has been obtained to design selective 11β-HSD1 blockers based on the oleanan and ursan scaffold.
Introduction
In humans, the ratio of active/inactive glucocorticoids is controlled by two enzyme isoforms:
11β-hydroxysteroid dehydrogenase type 1 and type 2 (11β-HSD1 and 11β-HSD2, respectively) (Seckl, 2004) . 11β-HSD1 converts cortisone to the active glucocorticoid cortisol, thereby controlling access of glucocorticoid hormones to the glucocorticoid receptor (Seckl, 2004) . Overexpression of 11β-HSD1 has been shown to play a crucial role in the onset of type 2 diabetes, and rodent models support the hypothesis that it might also be involved in the development of central obesity (Livingstone et al., 2000; Masuzaki et al., 2001; Liu et al., 2003) . 11β-HSD1 deficient mice show enhanced glucose tolerance, attenuated gluconeogenic responses and improved lipid and lipoprotein profiles (Kotelevtsev et al., 1997; Morton et al., 2001) . On the other hand, transgenic over-expression of 11β-HSD1 in mice adipose tissues causes visceral obesity, insulin resistance, diabetes, dyslipidemia and hypertension (Masuzaki et al., 2001; Masuzaki et al., 2003) . All these data suggest that selective inhibition of human 11β-HSD1 might become a new and promising approach for lowering blood glucose Page 3 of 15 A c c e p t e d M a n u s c r i p t 3 concentrations and for counteracting the accumulation of visceral fat and its related metabolic abnormalities in type 2 diabetes (reviewed in: (Hughes et al., 2008) ).
Triterpenoids like carbenoxolone, dexamethasone or glycyrrhetinic acid are non-selective inhibitors of 11β-HSD since they also inhibit 11β-HSD2, the second isoform (Stewart et al., 1987; Walker et al., 1995) . 11β-HSD2 acts as a dehydrogenase by converting active cortisol into inactive cortisone, thereby preventing inappropriate mineralocorticoid receptor activation by glucocorticoids in aldosterone target tissues. Non-selective inhibition of 11β-HSD2 results in serious side-effects like sodium retention, hypokalaemia and hypertension (Sandeep et al., 2004) .
Pentacyclic triterpenes of the ursan and oleanan type are widespread in the plant kingdom and many of them have been described as physiological active compounds (Yoshikawa et al., 1997; Shimizu et al., 1997; Kim et al., 1998; Murakami et al., 2001) (Fig. 1 ). Clinical interests in ursan and oleanan type triterpenes relate to their anti-inflammatory, hypoglycemic, anti-virial and apoptosis inducing properties. As indicated above, 18β-glycyrrhetinic acid, a compound with an oleanan scaffold, is known as strong inhibitor of 11β-hydroxysteroid dehydrogenase activity but because of its non-selective behaviour, it cannot be used in therapy. However, the structure of 18β-glycyrrhetinic acid may serve as a lead in the chemical synthesis of new and selective 11β-HSD1 blockers.
Previously, we successfully purified 11β-HSD1 in an active state from human and mouse liver microsomes (Maser and Bannenberg, 1994; Maser et al., 2002) . Furthermore, we produced recombinant human 11β-HSD1 enzyme by overexpression of the corresponding gene in E. coli and P. pastoris (Maser and Bannenberg, 1994; Blum et al., 2000; Maser et al., 2002) . In the present investigation, we performed studies on potential and selective 11β-HSD1 inhibitors. We present new compounds with an oleanan or ursan scaffold which selectively inhibit 11β-HSD1 in the nM range, whereas 11β-HSD2 activity is affected only in µM concentrations of the inhibitor. Furthermore, we discuss the structural determinants that confer 11β-HSD1 specificity to these compounds and show new approaches to synthesize 
Preparation of biological fractions
Enzymatically active 11β-HSD1 fractions (purified human 11β-HSD1, human liver microsomes, as well as recombinant 11β-HSD1 overexpressed in E. coli and P. pastoris) were prepared as previously described (Blum et al., 2000; Maser et al., 2002) . Human placental microsomes containing 11-HSD2 were prepared as follows: The placenta samples were homogenized in 4 volumes of homogenization buffer (20 mM Tris/HCl, 250 mM sucrose, 1 mM EDTA, 0.1 mM PMSF, pH 7.4) using a glass-Teflon Potter-Elvehjem homogenizer. The homogenate was centrifuged at 600 x g for 10 min and at 10000 x g for 10 min to sediment nuclei, cell debris and mitochondria. The supernatant at this stage was centrifuged at 170.000
x g for 1 h to sediment the microsomes. The microsomal pellet was resuspended in the homogenization buffer finally yielding a protein concentration of about 20 mg/ml.
Synthesis of selective 11β-HSD1 inhibitors.
To elucidate the structural determinants of oleanan and ursan type triterpenes which confer 11β-HSD1 specific inhibition, a variety of pentacyclic triterpenes was prepared from 18βglycyrrhetinic acid or other commercially available oleanan and ursan type triterpenes as starting material. The preparation was performed according to standard protocols of chemical synthesis and is described in detail under patent application PCT/DE 2007 / 002218.
Enzyme Assays
For analysis of 11-HSD1 reductase inhibition the carbonyl reduction of cortisone to cortisol was measured. The assay performed contained an NADPH-regenerating system and was incubated for 3h at 37°C. For analysis of 11-HSD1 dehydrogenase inhibition the oxidation of cortisol to cortisone was assayed in the presence of NADP and an incubation time of 60 min. Inhibition experiments were performed with human liver microsomes containing 11β-HSD1, with microsomes isolated from P. pastoris strains expressing recombinant human 11β-HSD1, and with purified 11β-HSD1 from human liver. For 11β-HSD2 inhibition experiments human placental microsomes were used. The assay conditions for 11-HSD2 inhibition corresponded to those for 11β-HSD1. All experiments have been done at least five times. The inhibition experiments of 11β-HSD1 activity, using different 11β-HSD1 preparations, resulted in similar inhibition pattern. The glucocorticoid concentration in the assays was 2 µM. M a n u s c r i p t 5
Docking simulations
For all docking calculations we used the crystal structure of 11β-HSD type 1 available at the Protein Data Bank (PDB) (Berman et al., 2000) in complex with carbenoxolone (PDB code 2bel). The protein structure was treated with the protein preparation wizard in Maestro (Maestro, 2007) whilst the simulations were performed using Glide (Glide, 2007) , both from the Schrödinger suite of programs. The ligands dataset was manually built in Maestro. During the protein preparation all water molecules were removed, hydrogen atoms were added and the complex was energy minimised using the default settings. The enclosing docking box, whose size in each direction was 27.5 Å, was centred on the nicotinamide C4 atom. The docking runs were performed in Standard Precision (SP) mode and in order to soften the potential for non polar parts of the ligands, the van der Walls radii of ligand atoms with partial atomic charge less than 0.15 were scaled by 0.8. Only the top 5 energy ranked poses were retained and energy minimised for each studied compound: The top scoring conformer for each ligand was identified on the basis of the Emodel score whilst the subsequent comparison between different compounds was performed taking into account their corresponding Gscore values (this is a recommended procedure in Glide).
Results and Discussion
Some triterpenoids like carbenoxolone, dexamethasone or glycyrrethinic acid are already known to inhibit 11β-HSD1 but their use in therapy is limited by the fact that they block the activity of 11β-HSD2 as well, thereby provoking renal mineralocorticoid excess at higher dosage (Stewart et al., 1987; Walker et al., 1995; Walker and Seckl, 2003) . Clinical interest in pentacyclic ursan and oleanan type triterpenes relate to their anti-inflammatory, anti-viral, apoptosis inducing and hypoglycemic properties, although the underlying mechanism in most cases is still unknown (Bühler et al., 1991; Matsuda et al., 1998) . Corosolic acid, an ursan type triterpene isolated from the leaf of Banaba (Lagerstroemia speciosa), a traditional oriental medicine to treat diabetes, induces GLUT4 translocation and lowers plasma insulin levels in KK-Ay mice (Miura et al., 2004) . Oleanoic acid, an oleanan type triterpene found in many plants with hypoglycemic activity e.g. M. charantia, G. sylvestre, exhibits the hypoglycemic activity on oral glucose-loaded rats by decreasing the rate of gastric emptying and inhibiting the glucose transport system at the small intestinal brush border (Matsuda et al., 1998) .
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A c c e p t e d M a n u s c r i p t 6 18β-Glycyrrhetinic acid, an oleanan type triterpene and principal active ingredient of liquorice root, as well as its hemisuccinyl derivate carbenoxolone are potent inhibitors of 11β-HSD activity (Stewart et al., 1987; Hult et al., 2006) , but display poor selectivity towards the two isoforms. Carbenoxolone has earlier been demonstrated to improve insulin sensitivity and to decrease glucose production in healthy human volunteers, but the 11β-HSD2 inhibitory activity of carbenoxolone was a limiting factor because it induces renal mineralocorticoid excess at higher dosis (Walker et al., 1995) . By using 18β-glycyrrhetinic as a lead structure, we prepared a variety of pentacyclic triterpenes from or other commercially available compounds (PCT/DE 2007 / 002218).
The results of our investigation emphasise the importance of a carbonyl group in 11-position of the pentacyclic scaffold for selective 11β-HSD1 recognition, whereas an acidic function in 20-position is responsible for a strong, non-selective inhibition of both 11β-HSD isoenzymes (Fig. 2) . Cleavage or masking of the acidic function of 18β-glycyrrhetinic acid resulted in selective 11β-HSD1 inhibition. Thereby, the selective inhibitory potency of the compound can be modulated by selection of the substituent in 20-position.
The comparison between oleanan and ursan triterpenes revealed that the methyl group in 19position of ursan type is accountable for a weak selective inhibition of 11β-HSD1. The presence of a keto-function in 11-position enhanced the overall inhibition, whereas an acidic function in 4-position affects the recognition of the 11-keto-function by 11β-HSD1, resulting in high IC 50 values (Fig .2) .
In Fig. 3 the putative binding mode of the most selective compound of the series (Cpd04) is compared to carbenoxolone binding mode as found in the X-ray structure deposited at the PDB (PDB code 2bel). The inhibitor is stabilised in the binding cleft mainly by hydrophobic interactions. Moreover a hydrogen bond between the carbonyl group of the ligand and the hydroxyl group of a serine (S170) ensures further stabilisation (see Fig. 3B ). Interestingly enough, experimental evidence shows that the non selective inhibitor carbenoxolone binds the enzyme in a similar fashion (see Fig. 3A ). The condensed cycles of both inhibitors appear surrounded mainly by hydrophobic side chains while few polar interactions are established with the protein thanks to their carbonyl (Cpd04 and CBO) and carboxyl (CBO) functional groups. Furthermore, as shown in Fig. 4 , the good correlation found between experimentally obtained pIC 50 values and calculated docking scores (Gscores), for the molecules in the dataset, highlights the robustness of the chosen docking method in producing reliable poses.
All the compounds docked the protein in a similar way.
A c c e p t e d M a n u s c r i p t 7 Selective 11β-HSD1 inhibitors that act in all tissues, particularly in adipocytes and skeletal muscles, have considerable potential as a drug directed against glucocorticoid related metabolic disorders. In particular, these inhibitors will improve insulin sensitivity and glucose uptake, reduce lipolysis, and counteract accumulation of visceral fat and its related metabolic abnormalities. Our findings highlight the possibility of obtaining potent selective 11β-HSD1 inhibitors based on the triterpene scaffold of the oleanan and ursan types. Selective 11β-HSD1 inhibitors, based on those moieties, should have the advantage of low toxicity, the possibility of operating modifications of the scaffold to influence pharmacokinetic and pharmacodynamic properties, and sufficient resources in nature to get enough starting material. Finally, the good correlation between experimental data and docking calculations is currently used to design more potent and selective 11β-HSD1 inhibitors. M a n u s c r i p t 8 Legends to the Figures   Fig.1 .
Ursan and oleanan type triterpenes. Residues S170, Y183, NADPH cofactor, carbenoxolone and Cpd04 are highlighted as dark grey and yellow coloured stick models, respectively. The dashed lines are drawn between atoms likely involved in H-bond interactions. 
